glp 1 comprimé Rewriting the Patient Journey: GLP‑1 Drugs and the Rise of Oral Therapies As GLP-1 Use Expands, Long-Term

Purpose-built for physicians Societies take stand against off-brand GLP-1s over safety concerns A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical organizations to speak out about safety concerns

GLP-1s facilitate weight loss by regulating appetite

Avoid the use of Qsymia with other drugs that inhibit carbonic anhydrase (e.g., zonisamide, acetazolamide or methazolamide)

A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice

*Biol Sport*

Most plans want documentation of prior weight loss attempts (diet apps, coaching, nutrition programs, etc.) and comorbidities Know what documentation details: For CVD prevention (Wegovy): Document prior MI, stroke, PAD, or revascularization